Category Pharma/Biotech

Otsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed…

Read MoreOtsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia

Enanta Pharmaceuticals Announces Fiscal First Quarter Financial Results for December 31, 2023, Hosting Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs within virology and immunology, has released its financial results for the fiscal first quarter ending December…

Read MoreEnanta Pharmaceuticals Announces Fiscal First Quarter Financial Results for December 31, 2023, Hosting Webcast and Conference Call Today at 4:30 p.m. ET

Longboard Pharmaceuticals Discloses Inducement Grants in Accordance with Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to pioneering transformative medicines for neurological diseases, has officially granted inducement awards to five new employees. The Compensation Committee of the Board of…

Read MoreLongboard Pharmaceuticals Discloses Inducement Grants in Accordance with Nasdaq Listing Rule 5635(C)(4)

Napp Secures Approval for REZZAYO® from the UK Medicines and Healthcare Products Regulatory Agency for Treating Invasive Candidiasis in Adults.

For Exclusive Distribution to GB Trade and Medical Media REZZAYO® (rezafungin) is approved for treating invasive candidiasis in adults. Adherence to official guidelines regarding the appropriate use of antifungal agents…

Read MoreNapp Secures Approval for REZZAYO® from the UK Medicines and Healthcare Products Regulatory Agency for Treating Invasive Candidiasis in Adults.